药物与车祸

中国药物警戒 ›› 2012, Vol. 9 ›› Issue (3): 173-177.

药物与车祸

周密妹，郭梅，尹丽芳

武汉科技大学附属天佑医院临床药学室，湖北武汉 430064

收稿日期:2011-07-01 出版日期:2012-03-10 发布日期:2015-08-10
作者简介:周密妹，女，主任药师，临床药学。

Medicines and Vehicle Crashes

ZHOU Mi-mei, GUO Mei, YIN Li-fang

Affiliated Hospital of Wuhan University of Science and Technology, Hubei Wuhan 430064, China

Received:2011-07-01 Online:2012-03-10 Published:2015-08-10

摘要/Abstract

摘要： 能作用于中枢神经系统、血糖、血压、视力以及对驾驶功能有妨碍的药物为潜在驾驶者伤害药物，此类药物包括中枢神经系统药物、抗组胺药、抗高血压药、抗糖尿病药、镇痛药等，其主要不良表现为镇静、嗜睡、眩晕、低血压、低血糖、视力模糊、动作失调等。有必要对这类药害事件提高警惕并采取有效防范措施。

关键词: 药物, 驾驶者伤害, 车祸

Abstract: Medicines that have known effects on the central nervous system, blood glucose levels, blood pressure, vision, or otherwise have the potential to interfere with driving skills have been termed "potentially driver-impairing" (PDI). These mcdicines include CNS depressants, antihistamine, antihypertensive drugs, hypoglycemics, pain relievers etc. PDI effects include sedation, drowsiness, dizziness, hypotension, hypoglycemia, blurred vision and loss of coordination. It is important to increase awareness among health care providers and drivers regarding the potential driver impairing effects of pharmaceutical use.

Key words: medicines, potentially driver-impairing, vehicle crashes

周密妹，郭梅，尹丽芳. 药物与车祸[J]. 中国药物警戒, 2012, 9(3): 173-177.

ZHOU Mi-mei, GUO Mei, YIN Li-fang. Medicines and Vehicle Crashes[J]. Chinese Journal of Pharmacovigilance, 2012, 9(3): 173-177.

参考文献

[1] Leroy A, Morse MM, for US DOT/NHTSA. Exploratory study of?the relationship between multiple medications and vehicle?crashes. Was-hington,DC:U.S.DOT/NHTSA;2008[EB/OL].http://www.nhtsa.gov/DOT/NHTSA/810858.pdf. Accessed December 4, 2010.
[2] Couper FJ, Logan BK for US DOT/NHTSA.Drugs and human performance fact sheets.Washington,DC:2004[EB/OL].http://www.nhtsa.dot.gov/people/injury/drugs_web.pdf.Accessed December 4, 2010.
[3] Thomson Healthcare eds. Donnatal Extentabs prescribing information. In: Physicians' Desk Reference[M]. 2009. 63d ed. New York, NY: Thomson Reuters, 2009:2507.
[4] Stefanacci RG, Cavallaro E, Beers MH, et al. Developing explicit positive beers criteria for preferred central nervous system medications in older adults[J]. Consult Pharm. 2009;24:601-610.
[5] Hebert C, Delaney JA, Hemmelgarn B,et al. Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs[J]. Pharmacoepidemiol Drug Saf. 2007;16:845-849.
[6] Meskali M, Berthelon C, Marie S, et al. Residual effects of hypnotic drugs in aging drivers submitted to simulated accident scenarios: an exploratory study[J]. Psychopharmacology.2009; 207(3):461-467.
[7] Ramaekers J. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test[J]. J Clin Psychiatry. 2003;64:20-29.
[8] Fluoxetine hydrochloride. US FDA, CDER website. Rockaway, NJ: Eli Lilly and Company[EB/OL]. May 4, 2009. http://www.accessdata.fda.gov/drugsatfda_docs.Accessed December 14, 2009.
[9] Trazodone hydrochloride. Princeton, NJ: Bristol-Myers Squibb[EB/OL]. February 2009. http://packageinserts.bms.com/pi. Accessed December 14, 2009.
[10] Venlafaxine hydrochloride. US FDA, CDER website. Philadelphia, Pa: Wyeth Pharmaceuticals[EB/OL].November, 2008. http://www.wyeth.com/content. Accessed December 10, 2010.

[1]	郭宁子, 刘丽, 岳瑞齐, 冯慧庆, 杨化新, 魏宁漪, 陈华. 激光衍射法测定西格列他钠粒径分布[J]. 中国药物警戒, 2024, 21(2): 147-151.
[2]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[3]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[4]	靳生菊, 周苗, 张佳宁, 葛宫慧, 张廷剑, 孟繁浩. 新型黄嘌呤氧化酶抑制剂对痛风治疗的研究进展[J]. 中国药物警戒, 2024, 21(2): 223-228.
[5]	王欣, 史磊磊, 张雨涵, 谢允东, 刘继平. 多药耐药相关蛋白转运体在药物性肝损伤中的作用研究进展[J]. 中国药物警戒, 2024, 21(2): 229-234.
[6]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[7]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[8]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[9]	高旭, 彭金娥, 李兴旺, 张伟. 猴痘抗病毒药物及疫苗研究现状[J]. 中国药物警戒, 2024, 21(1): 111-116.
[10]	詹姆斯·布坎南. 用 nR 改良海氏法则及 P_ALT 评估药物性肝损伤研究进展[J]. 中国药物警戒, 2024, 21(1): 117-120.
[11]	马瑞泽, 陈志海. 抗新型冠状病毒的小分子药物最新研究进展[J]. 中国药物警戒, 2023, 20(9): 961-966.
[12]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.